Physiomics
Physiomics helps biotech and pharma make better development decisions using mathematical modelling, simulation and biometrics expertise. Through Model-Informed Drug Development (MIDD), we provide the quantitative evidence needed to de-risk development, maximise asset value and accelerate the path to patients. From candidate selection, dose optimisation and combination strategy to clinical development planning, study design and regulatory interactions, we provide data-driven evidence to answer the critical R&D questions that determine the success of a therapeutic programme.
